Form 4: Denali Therapeutics Director Vicki L. Sato Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics Inc. (DNLI) common stock at an average price of $20.10, executed under a pre-arranged 10b5-1 trading plan.
Summary
- On March 15, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 1,666 shares of common stock.
- The sale was executed at a weighted average price of $20.10 per share, with individual prices ranging from $19.72 to $20.31.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 29, 2023.
- Following the transaction, Sato directly owns 119,709 shares of Denali Therapeutics, including 4,216 unvested RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Sales by company directors are a normal part of corporate governance. Investors often monitor these sales to understand insider sentiment, but sales under 10b5-1 plans are pre-arranged and may not reflect current sentiment.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023/09/29 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024/03/15 | Date of transaction (stock sale). |
| 2024/03/19 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.